Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
about
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@en
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@nl
type
label
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@en
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@nl
prefLabel
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@en
Risk of febrile neutropenia an ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P356
P1476
Risk of febrile neutropenia an ...... tion-resistant prostate cancer
@en
P2093
Ainsley Campbell
Alice Bergin
Andrew D Vincent
Andrew J Weickhardt
Babak Tamjid
Carmel Pezaro
Josephine Stewart
Kaspar Willson
P2860
P304
P356
10.1111/AJCO.12840
P50
P577
2018-01-10T00:00:00Z